Abbott’s investigational treatment, ABT-874, has been found significantly effective in reducing the symptoms of psoriasis in majority of patients treated.
Such were the findings from the new Phase II clinical data recently reported by Abbott (NYSE: ABT).
At 12 weeks, nine out of 10 patients with moderate to severe psoriasis achieved 75 percent improvement in psoriasis signs and symptoms in four of the five dosing groups receiving ABT-874, versus 3 percent of patients receiving placebo.
Also, more than half of patients achieved 90 percent improvement, in the same four of five ABT-874 dosing groups, versus 0 percent of those receiving placebo.
ABT-874 targets a part of the inflammatory response (interleukin-12 and interleukin-23, two proteins associated with inflammation in psoriasis and other autoimmune disorders) that is not addressed by any therapy against psoriasis currently available.
Phase III psoriasis studies with ABT-874 are scheduled later this year.
Findings will be presented by Abbott this coming week at the Society for Investigative Dermatology annual meeting in Los Angeles.
Find more details from the press release.
Its great that there is improvement in 90 percent patients.
Here is an video for Psoriasis Treatment.Watch this
http://video.google.com/videoplay?docid=8631418832951011712
Posted by: Ray | June 13, 2007 1:46 AM | Permalink to Comment